Treatment of breast cancer during pregnancy: an observational study

S Loibl, SN Han, G von Minckwitz, Marijke Bontenbal, A Ring, J Giermek, T Fehm, K Van Calsteren, SC Linn, B Schlehe, MM Gziri, PJ (Pieter) Westenend, V Muller, L Heyns, B Rack, BJ Calster, N Harbeck, M Lenhard, MJ Halaska, M KaufmannV Nekljudova, F Amant

Research output: Contribution to journalArticleAcademicpeer-review

186 Citations (Scopus)

Abstract

Background Little is known about the treatment of breast cancer during pregnancy. We aimed to determine whether treatment for breast cancer during pregnancy is safe for both mother and child. Methods We recruited patients from seven European countries with a primary diagnosis of breast cancer during pregnancy; data were collected retrospectively if the patient was diagnosed before April, 2003 (when the registry began), or prospectively thereafter, irrespective of the outcome of pregnancy and the type and timing of treatment. The primary endpoint was fetal health for up to 4 weeks after delivery. The registry is ongoing. The study is registered with ClinicalTrials.gov, number NCT00196 Findings From April, 2003, to December, 2011, 447 patients were registered, 413 of whom had early breast cancer. Median age was 33 years (range 22-51). At the time of diagnosis, median gestational age was 24 weeks (range 5-40). 197 (48%) of 413 women received chemotherapy during pregnancy with a median of four cycles (range one to eight). 178 received an anthracycline, 15 received cyclophosphamide, methotrexate, and fluorouracil, and 14 received a taxane. Birthweight was affected by chemotherapy Interpretation Although our data show that infants exposed to chemotherapy in utero had a lower birthweight at gestational age than did those who were unexposed, and had more complications, these differences were not clinically significant and, since none of the infants was exposed to chemotherapy in the first trimester, were most likely related to premature delivery. Delay of cancer treatment did not significantly affect disease-free survival for mothers with early breast cancer. Because preter
Original languageUndefined/Unknown
Pages (from-to)887-896
Number of pages10
JournalLancet Oncology
Volume13
Issue number9
DOIs
Publication statusPublished - 2012

Cite this